{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,9,19]],"date-time":"2025-09-19T07:46:26Z","timestamp":1758267986465,"version":"3.44.0"},"reference-count":26,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"31","license":[{"start":{"date-parts":[[2025,8,1]],"date-time":"2025-08-01T00:00:00Z","timestamp":1754006400000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"funder":[{"name":"Fundaci\u00c3\u00b3n para la Investigaci\u00c3\u00b3n e Innovaci\u00c3\u00b3n Biom\u00c3\u00a9dica del Hospital Universitario Infanta Sof\u00c3a y Hospital Universitario del Henares y Hospital del Tajo","award":["FHH20\/ COVID07"],"award-info":[{"award-number":["FHH20\/ COVID07"]}]}],"content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2025,8,1]]},"abstract":"<jats:p>Since the development of vaccines for coronavirus disease 2019 (COVID-19), the course of infections has changed significantly. Over the past 4 years of coexisting with the virus, a marked improvement in disease outcomes has been observed, especially in patients with rheumatological diseases; this is largely attributable to widespread immunization. This study aimed to evaluate the perception of COVID-19 vaccine protection and to describe the incidence and severity of COVID-19 in the pre- and post-vaccination periods among different patient typologies and immunosuppressive treatments in rheumatology patients. This study used observational, descriptive\u2013analytical, ambispective, and cross-sectional methods. We administered a questionnaire in the rheumatology department to patients with immune-mediated inflammatory diseases (IMID), with or without disease-modifying antirheumatic drugs, including conventional synthetic drugs, biological drugs, and targeted synthetic drugs, and to patients with musculoskeletal conditions (non-autoimmune patients). All patients received at least 2 doses of the COVID-19 vaccine. A total of 407 patients, with a mean age and standard deviation 59.1\u2005\u00b1\u200513.6 and 66.1% female, were studied. Most patients (78.1%) reported feeling protected or very protected by the COVID-19 vaccine, with the perception of safety ranging from 66.9% to 87.5% across different patient typologies. The proportion of patients who felt protected or very protected was significantly lower in the non-autoimmune group (63.9%) than in the IMID patients treated with conventional synthetic drugs (87.5%) or biological drugs [excluding CD-20 inhibitors (rituximab)] and targeted synthetic drugs (82.1%) (<jats:italic toggle=\"yes\">P<\/jats:italic>\u2005&lt;\u2005.001 and <jats:italic toggle=\"yes\">P<\/jats:italic>\u2005=\u2005.011, respectively). There were no significant differences in the incidence of COVID-19 infection or in the severity of its clinical presentation (in both the pre- and post-vaccination stages) among the different typologies of patients, or in relation to the immunosuppressive therapy they received. Patients with IMID who received immunosuppressive treatment reported higher levels of perceived protection after COVID-19 vaccination. However, the incidence and severity of COVID-19 were similar between patients with and without IMIDs. This study supports the importance of infection prevention in these patients and emphasizes the need for closely monitored vaccination programs.<\/jats:p>","DOI":"10.1097\/md.0000000000043618","type":"journal-article","created":{"date-parts":[[2025,8,1]],"date-time":"2025-08-01T23:02:44Z","timestamp":1754089364000},"page":"e43618","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":0,"title":["Perception of COVID-19 vaccines in rheumatology patients"],"prefix":"10.1097","volume":"104","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-1313-5225","authenticated-orcid":false,"given":"Liz","family":"Romero-Bogado","sequence":"first","affiliation":[{"name":"Rheumatology Section, Hospital Universitario Infanta Sof\u00eda, FIIB HUIS HHEN, Universidad Europea de Madrid, Madrid, Spain"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Martina","family":"Steiner","sequence":"additional","affiliation":[{"name":"Rheumatology Section, Hospital Universitario Infanta Sof\u00eda, FIIB HUIS HHEN, Universidad Europea de Madrid, Madrid, Spain"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Cristina","family":"Andreu-V\u00e1zquez","sequence":"additional","affiliation":[{"name":"Faculty of Biomedical and Health Sciences, Universidad Europea de Madrid, Madrid, Spain."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Israel John","family":"Thuissard-Vasallo","sequence":"additional","affiliation":[{"name":"Faculty of Biomedical and Health Sciences, Universidad Europea de Madrid, Madrid, Spain."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tatiana","family":"Cobo-Ib\u00e1\u00f1ez","sequence":"additional","affiliation":[{"name":"Rheumatology Section, Hospital Universitario Infanta Sof\u00eda, FIIB HUIS HHEN, Universidad Europea de Madrid, Madrid, Spain"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Isabel","family":"de la C\u00e1mara-Fern\u00e1ndez","sequence":"additional","affiliation":[{"name":"Faculty of Biomedical and Health Sciences, Universidad Europea de Madrid, Madrid, Spain."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ana","family":"Esteban-V\u00e1zquez","sequence":"additional","affiliation":[{"name":"Rheumatology Section, Hospital Universitario Infanta Sof\u00eda, FIIB HUIS HHEN, Universidad Europea de Madrid, Madrid, Spain"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"M. Beatriz","family":"Paredes-Romero","sequence":"additional","affiliation":[{"name":"Rheumatology Section, Hospital Universitario Infanta Sof\u00eda, FIIB HUIS HHEN, Universidad Europea de Madrid, Madrid, Spain"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Patricia","family":"Richi-Alberti","sequence":"additional","affiliation":[{"name":"Rheumatology Section, Hospital Universitario Infanta Sof\u00eda, FIIB HUIS HHEN, Universidad Europea de Madrid, Madrid, Spain"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Laura","family":"Trives-Folguera","sequence":"additional","affiliation":[{"name":"Rheumatology Section, Hospital Universitario Infanta Sof\u00eda, FIIB HUIS HHEN, Universidad Europea de Madrid, Madrid, Spain"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Cristina","family":"Vergara-Dangond","sequence":"additional","affiliation":[{"name":"Rheumatology Section, Hospital Universitario Infanta Sof\u00eda, FIIB HUIS HHEN, Universidad Europea de Madrid, Madrid, Spain"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Elisabet","family":"Casta\u00f1eda","sequence":"additional","affiliation":[{"name":"Rheumatology Section, Hospital Universitario Infanta Sof\u00eda, FIIB HUIS HHEN, Universidad Europea de Madrid, Madrid, Spain"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ana V.","family":"Acosta-Alfaro","sequence":"additional","affiliation":[{"name":"Rheumatology Section, Hospital Universitario Infanta Sof\u00eda, FIIB HUIS HHEN, Universidad Europea de Madrid, Madrid, Spain"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Gabriela","family":"Cueva-N\u00e1jera","sequence":"additional","affiliation":[{"name":"Rheumatology Section, Hospital Universitario Infanta Sof\u00eda, FIIB HUIS HHEN, Universidad Europea de Madrid, Madrid, Spain"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Rosa","family":"S\u00e1nchez-D\u00edaz","sequence":"additional","affiliation":[{"name":"Rheumatology Section, Hospital Universitario Infanta Sof\u00eda, FIIB HUIS HHEN, Universidad Europea de Madrid, Madrid, Spain"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Encarnaci\u00f3n","family":"Puerto-Mu\u00f1oz","sequence":"additional","affiliation":[{"name":"Rheumatology Section, Hospital Universitario Infanta Sof\u00eda, FIIB HUIS HHEN, Universidad Europea de Madrid, Madrid, Spain"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Santiago","family":"Mu\u00f1oz-Fern\u00e1ndez","sequence":"additional","affiliation":[{"name":"Rheumatology Section, Hospital Universitario Infanta Sof\u00eda, FIIB HUIS HHEN, Universidad Europea de Madrid, Madrid, Spain"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"276","reference":[{"key":"R1-20250918","doi-asserted-by":"crossref","first-page":"1199","DOI":"10.1007\/s10067-023-06825-z","article-title":"The effect of COVID-19 infection on patients with rheumatic diseases in China.","volume":"43","author":"Lai","year":"2024","journal-title":"Clin Rheumatol"},{"key":"R2-20250918","doi-asserted-by":"crossref","first-page":"1435","DOI":"10.1111\/1756-185X.14766","article-title":"The outcome of COVID-19 in patients with autoimmune rheumatic diseases: comparable to the general population or worse?","volume":"26","author":"Batu","year":"2023","journal-title":"Int J Rheum Dis"},{"key":"R3-20250918","first-page":"100843","article-title":"Omicron variant infection in inflammatory rheumatological conditions \u2013 outcomes from a COVID-19 naive population in Aotearoa New Zealand.","volume":"38","author":"Brooks","year":"2023","journal-title":"Lancet Reg Health West Pac"},{"key":"R4-20250918","doi-asserted-by":"crossref","first-page":"e348","DOI":"10.1097\/RHU.0000000000001716","article-title":"Incidence of COVID-19 in 902 patients with immunomediated inflammatory diseases treated with biologics and targeted synthetic disease-modifying antirheumatic drugs-findings from the BIOCOVID study.","volume":"28","author":"Mu\u00f1oz-Fern\u00e1ndez","year":"2022","journal-title":"J Clin Rheumatol"},{"key":"R5-20250918","doi-asserted-by":"crossref","first-page":"1600","DOI":"10.1002\/art.41388","article-title":"Incidence of COVID-19 in patients with rheumatic diseases treated with targeted immunosuppressive drugs: what can we learn from observational data?","volume":"72","author":"Favalli","year":"2020","journal-title":"Arthritis Rheumatol"},{"key":"R6-20250918","doi-asserted-by":"crossref","first-page":"e245","DOI":"10.1136\/annrheumdis-2020-218400","article-title":"No increased rate of SARS-CoV-2 infection for patients with inflammatory rheumatic diseases compared with the general population in the city of Hamburg (Germany).","volume":"81","author":"Aries","year":"2022","journal-title":"Ann Rheum Dis"},{"key":"R7-20250918","doi-asserted-by":"crossref","first-page":"885","DOI":"10.1016\/j.semarthrit.2020.07.012","article-title":"Incidence and clinical course of COVID-19 in patients with rheumatologic diseases: a population-based study.","volume":"50","author":"So","year":"2020","journal-title":"Semin Arthritis Rheum"},{"key":"R8-20250918","doi-asserted-by":"crossref","first-page":"1047","DOI":"10.1093\/rheumatology\/keac422","article-title":"Different COVID-19 outcomes among systemic rheumatic diseases: a nation-wide cohort study.","volume":"62","author":"Bournia","year":"2023","journal-title":"Rheumatology (Oxford)"},{"key":"R9-20250918","doi-asserted-by":"crossref","first-page":"203","DOI":"10.46497\/ArchRheumatol.2024.10313","article-title":"Pandemic of the century: COVID-19 in inflammatory rheumatic diseases of a national cohort with 3,532 patients.","volume":"39","author":"Yurdakul","year":"2024","journal-title":"Arch Rheumatol"},{"key":"R10-20250918","doi-asserted-by":"crossref","first-page":"1170","DOI":"10.1136\/annrheumdis-2020-217763","article-title":"Prevalence of hospital PCR-confirmed COVID-19 cases in patients with chronic inflammatory and autoimmune rheumatic diseases.","volume":"79","author":"Pablos","year":"2020","journal-title":"Ann Rheum Dis"},{"key":"R11-20250918","doi-asserted-by":"crossref","first-page":"741","DOI":"10.1002\/acr.24831","article-title":"Increased risk of COVID-19 in patients with rheumatoid arthritis: a general population-based cohort study.","volume":"74","author":"Wang","year":"2022","journal-title":"Arthritis Care Res (Hoboken)"},{"key":"R12-20250918","doi-asserted-by":"crossref","first-page":"956","DOI":"10.1002\/acr.25028","article-title":"Risk of COVID-19 among unvaccinated and vaccinated patients with rheumatoid arthritis: a general population study.","volume":"75","author":"Li","year":"2023","journal-title":"Arthritis Care Res (Hoboken)"},{"key":"R13-20250918","doi-asserted-by":"crossref","first-page":"113","DOI":"10.4172\/2471-9544.100113","article-title":"What can we do to prevent infections in adult patients with rheumatic diseases?","volume":"2","author":"Richi","year":"2016","journal-title":"J Vasc"},{"key":"R14-20250918","doi-asserted-by":"crossref","first-page":"258","DOI":"10.1016\/S0140-6736(14)61704-9","article-title":"Risk of serious infection in the biological treatment of patients with rheumatoid arthritis: a systematic review and meta-analysis.","volume":"386","author":"Singh","year":"2015","journal-title":"Lancet"},{"key":"R15-20250918","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1016\/j.jare.2018.09.003","article-title":"Risk of serious infection among patients receiving biologics for chronic inflammatory diseases: usefulness of administrative data.","volume":"15","author":"Quartuccio","year":"2018","journal-title":"J Adv Res"},{"key":"R16-20250918","doi-asserted-by":"crossref","first-page":"2994","DOI":"10.1016\/j.vaccine.2024.03.067","article-title":"Self-reported determinants of COVID-19 vaccine acceptance among persons with and without autoimmune disease.","volume":"42","author":"Gong","year":"2024","journal-title":"Vaccine"},{"key":"R17-20250918","doi-asserted-by":"crossref","first-page":"1124548","DOI":"10.3389\/fpubh.2023.1124548","article-title":"The pattern from the first three rounds of vaccination: declining vaccination rates.","volume":"11","author":"Wu","year":"2023","journal-title":"Front Public Health"},{"key":"R18-20250918","doi-asserted-by":"crossref","first-page":"457","DOI":"10.1007\/s10238-022-00832-1","article-title":"Attitudes towards and safety of the SARS-CoV-2 inactivated vaccines in 188 patients with systemic lupus erythematosus: a post-vaccination cross-sectional survey.","volume":"23","author":"Tang","year":"2023","journal-title":"Clin Exp Med"},{"key":"R19-20250918","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1186\/s41927-023-00338-7","article-title":"Attitudes and beliefs towards COVID-19 and COVID-19 vaccination among rheumatology patients in a Los Angeles County safety net clinic.","volume":"7","author":"Ward","year":"2023","journal-title":"BMC Rheumatol"},{"key":"R20-20250918","doi-asserted-by":"crossref","first-page":"143","DOI":"10.1136\/annrheumdis-2021-220549","article-title":"B-cell targeted therapy is associated with severe COVID-19 among patients with inflammatory arthritis: a 1-year multicentre study in 1116 successive patients receiving intravenous biologics.","volume":"81","author":"Felten","year":"2022","journal-title":"Ann Rheum Dis"},{"key":"R21-20250918","doi-asserted-by":"crossref","first-page":"e3","DOI":"10.1016\/S2665-9913(21)00362-3","article-title":"What does endemic COVID-19 mean for the future of rituximab?","volume":"4","author":"Liew","year":"2022","journal-title":"Lancet Rheumatol"},{"key":"R22-20250918","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1093\/rheumatology\/keac241","article-title":"COVID-19 infection and hospitalization risk according to vaccination status and DMARD treatment in patients with rheumatoid arthritis.","volume":"62","author":"Cordtz","year":"2022","journal-title":"Rheumatology (Oxford)"},{"key":"R23-20250918","doi-asserted-by":"crossref","first-page":"1156","DOI":"10.1136\/annrheumdis-2020-217888","article-title":"Clinical characteristics and outcomes of patients with coronavirus disease 2019 (COVID-19) and rheumatic disease: a comparative cohort study from a US \u201chot spot\u201d.","volume":"79","author":"D\u2019Silva","year":"2020","journal-title":"Ann Rheum Dis"},{"key":"R24-20250918","doi-asserted-by":"crossref","first-page":"870","DOI":"10.1111\/1756-185X.14662","article-title":"COVID-19 outcomes in patients with and without autoimmune rheumatic diseases: a multicenter comparative study.","volume":"26","author":"Abdulnaby","year":"2023","journal-title":"Int J Rheum Dis"},{"key":"R25-20250918","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1093\/rheumatology\/kead637","article-title":"Hospitalization, disease severity and mortality rates of patients with inflammatory rheumatic diseases as compared with the normal population in the second wave of SARS-CoV-2 infections.","volume":"64","author":"Dallagiacoma","year":"2025","journal-title":"Rheumatology (Oxford)"},{"key":"R26-20250918","doi-asserted-by":"crossref","first-page":"384","DOI":"10.1136\/annrheumdis-2020-218946","article-title":"Prevalence and clinical outcomes of COVID-19 in patients with autoimmune diseases: a systematic review and meta-analysis.","volume":"80","author":"Akiyama","year":"2021","journal-title":"Ann Rheum Dis"}],"container-title":["Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/10.1097\/MD.0000000000043618","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,9,18]],"date-time":"2025-09-18T22:02:13Z","timestamp":1758232933000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/10.1097\/MD.0000000000043618"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,8,1]]},"references-count":26,"journal-issue":{"issue":"31","published-print":{"date-parts":[[2025]]}},"URL":"https:\/\/doi.org\/10.1097\/md.0000000000043618","relation":{},"ISSN":["1536-5964"],"issn-type":[{"type":"electronic","value":"1536-5964"}],"subject":[],"published":{"date-parts":[[2025,8,1]]},"assertion":[{"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}}]}}